The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo-[4,3,- a]quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation

Molecular Pharmacology

Volumn 56, Issue 2, 1999, Pages 243-253

  Feelisch, Martin ^a   Kotsonis, Peter ^b   Siebe, Jan ^c   Clement, Bernd ^c   Schmidt, Harald H H W ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; ATRIOPEPTIN II; CYCLIC GMP; CYTOCHROME P450; DIAMINE; GLYCERYL TRINITRATE; GUANYLATE CYCLASE INHIBITOR; HISTAMINE; LINSIDOMINE; N ACETYL S NITROSOPENICILLAMINE; N [4 [1 (3 AMINO PROPYL) 2 HYDROXY 2 NITROSO HYDRAZINO]BUTYL] 1,3 PROPANE DIAMINE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PAPAVERINE; PEROXYNITRITE; PHENYLEPHRINE; PROTEIN INHIBITOR; S NITROSOGLUTATHIONE; SPERMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING; VASODILATATION;

EID: 0032793679     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.2.243     Document Type: Article

References (49)

1. Arnold WP, Mittal CK, Katsuki S and Murad F (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74:3203-3207.
2. Beckman JS, Chen J, Ischiropoulos H and Crow JP (1994) Oxidative chemistry of peroxynitrite. Methods Enzymol 233:229-240.
3. Beckman JS and Koppenol WH (1996) Nitric oxide, Superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol Cell Physiol 40:C1424-C1437.
4. Böhme E, Graf H and Schultz G (1978) Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets. Adv Cyclic Nucleotide Res 9:131-143.
5. Bolotina VM, Najibi S, Palatino JJ, Pagano PJ and Cohen RA (1994) Nitric oxide directly activates potassium channels in vascular smooth muscle. Nature (Lond) 368:850-853.
6. Boulton CL, Southam E and Garthwaite J (1995) Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience 69:699-703.
7. Bredt DS and Snyder SS (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87:682-685.
8. Brunner F, Schmidt K, Nielsen EB and Mayer B (1996) Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J Pharmacol Exp Ther 277:48-53.
9. Clement B, Schultze-Mosgau MH and Wohlers H (1993) Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reductions and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide. Biochem Pharmacol 46:2249-2267.
10. Brunner F, Stessel H and Kukovetz WR (1995) Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion. FEBS Lett 376:262-266.
11. Fedele E, Jin Y, Varnier G and Raiteri M (1996) In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor nitric oxide cyclic GMP pathway. Br J Pharmacol 119:590-594.
12. Feelisch M (1991) The biochemical pathways of nitric oxide formation from nitrova-sodilators: Appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol 17:S25-S33.
13. Feelisch M (1998) The use of nitric oxide donors in pharmacological studies. Naunyn-Schmiedeberg's Arch Pharmacol 358:113-122.
14. Feelisch M, Kubitzek D and Werringloer J (1996) The oxyhemoglobin assay, in Methods in Nitric Oxide Research (Feelisch M and Stamler JS eds) pp 455-478, John Wiley & Sons, Chichester, UK.
15. Field L, Dilts RV, Ravichandran R, Lenhert PG and Carnahan GE (1978) An unusually stable thionitrite from N-acetyl-D,L-penicillamine; X-ray crystal and molecular structure of 2-(acetylamino)-2-carboxy-1,1-dimethylethyl thionitrite. J Chem Soc Chem Commun 249-250.
16. Franck H, Sweeney KM, Sanders KM and Shuttleworth CW (1997) Effects of a novel guanylyl cyclase inhibitor on nitric oxide-dependent inhibitory neurotransmission in canine proximal colon. Br J Pharmacol 122:1223-1229.
17. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K and Mayer B (1995) Potent and selective inhibition of nitric oxide sensitive guanylyl cyclase by 1H-[1,2,4]oxodiazolo[4,3-α]quinoxalin-1-one. Mol Pharmacol 48:184-188.
18. Griess JP (1864) On a new series of bodies in which nitrogen is substituted for hydrogen. Philos Trans R Soc Lond 154:667-731.
19. Gryglewski RJ, Palmer RM and Moncada S (1986) Superoxide is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (Lond) 320: 454-456.
20. +-ATPase activity by nitric oxide: A cyclic GMP-independent effect. Am J Physiol 266:H2146-H2151.
21. Hart TW (1985) Some observations concerning the S-nitroso and S-phenylsulfonyl derivatives of L-cysteine and glutathione. Tetrahedron Lett 26:2013-2016.
22. Hussain AS, Marks GS, Brien JF and Nakatsu K (1997) The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-α]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Can J Physiol Pharmacol 75:1034-1037.
23. Ko F-N, Wu C-C, Kuo S-C, Lee F-Y and Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226-4233.
24. Koh SD, Campbell JD, Carl A and Sanders KM (1995) Nitric oxide activates multiple potassium channels in canine colonic smooth muscle. J Physiol (Lond) 489:735-743.
25. Li CG and Rand MJ (1996) Inhibition of NO-mediated responses by 7-ethoxyresorufin, a substrate and competitive inhibitor of cytochrome P450. Br J Pharmacol 118:57-62.
26. Lipton SA, Choi YB, Pan ZH, Lei SC, Chen HS, Sucher NJ, Loscalzo J, Singel DJ and Stamler JS (1993) A redox-based mechanism for the neuroprotective effects of nitric oxide and related nitroso-compounds. Nature (Lond) 364:626-632.
27. Liu LW, Thuneberg L, Daniel EE and Huizinga JD (1993) Selective accumulation of methylene blue by interstitial cells of Cajal in canine colon. Am J Physiol 264: G64-G73.
28. Mayer B, Brunner F and Schmidt K (1993) Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 45:367-374.
29. McDonald BJ and Bennett BM (1993) Biotransformation of glyceryl trinitrate by rat aortic cytochrome P450. Biochem Pharmacol 45:268-270.
30. Moncada S, Palmer RM and Higgs EA (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142.
31. Moro MA, Russell RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW and Moncada S (1996) cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 93:1480-1485.
32. Mülsch A, Bauersachs J, Schäfer A, Stasch J-P, Kast R and Busse R (1997) Effect of YC-1, an NO-independent, Superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689.
33. Mülsch A, Busse R, Liebau S, Forstermann U (1988) LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther 247:283-288.
34. Olesen S-P, Drejer J, Axeleson O, Moldt P, Bang L, Nielsen-Kudsk JE, Busse R and Mülsch A (1998) Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol 123:299-309.
35. Olson LJ, Knych Jr ET, Herzig TC and Drewett JG (1997) Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation. Hypertension 29:254-261.
36. Onoue H and Katusic ZS (1998) The effect of 1H-[1,2,4]oxadiazolo[4,3-α]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide. Brain Res 785:107-113.
37. Plane F, Hurrell A, Jeremy JY and Garland CJ (1996) Evidence that potassium channels make a major contribution to SIN-1 evoked relaxation of rat isolated mesenteric artery. Br J Pharmacol 119:1557-1562.
38. Schmidt HHW, Lohmann SL and Walter U (1993) The nitric oxide and cGMP signal-transduction pathway. Biochem Biophys Acta 1178:153-175.
39. Schmidt HHHW, Pollock JS, Nakane M, Gorsky LD, Förstermann U and Murad F (1991) Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA 88:365-369.
40. Schmidt HHHW and Walter U (1994) NO at work. Cell 78:919-925.
41. Schrammel A, Behrends S, Schmidt K, Koesling D and Mayer B (1996) Characterization of 1H-[1,2,4]oxadiazolo[4,3-α]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50:1-5.
42. Stamler JS (1994) Redox signalling: Nitrosylation and related target interactions of nitric oxide. Cell 78:931-936.
43. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ and Loscalzo J (1992) S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 89: 444-448.
44. van der Zypp, A and Majewski H (1998) Effect of cGMP inhibitors on the actions of nitrovasodilators in rat aorta. Clin Exp Pharmacol Physiol 25:38-43.
45. Wegener JW, Gath I, Förstermann U and Nawrath H (1997) Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br J Pharmacol 122:1523-1529.
46. Weisbrod RM, Griswold MC, Yaghoubi M, Komalavilas P, Lincoln TM and Cohen RA (1998) Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol 125:1695-1707.
47. Wolin MS, Cherry PD, Rodenburg JM, Messina EJ and Kaley G (1990) Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther 254:872-876.
48. Wu C-C, Ko F-N, Kuo S-C, Lee F-Y and Teng C-M (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116:1973-1978.
49. .) using L-cysteine. Biochem Biophys Res Commun 201:54-62.